Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease by Toth PP

Get full text

Dyslipidemia in women: etiology and management by Phan BAP, Toth PP

Get full text

Ezetimibe therapy: mechanism of action and clinical update by Phan BAP, Dayspring TD, Toth PP

Get full text

Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk St... by Toth PP, Philip S, Hull M, Granowitz C

Get full text

Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy by Toth PP, Thakker KM, Jiang P, Padley RJ

Get full text

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab by Blom DJ, Dent R, Castro RC, Toth PP

Get full text

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers by Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R

Get full text

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy by Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K

Get full text

Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease by Power TP, Ke X, Zhao Z, Bonine NG, Cziraky MJ, Grabner M, Barron JJ, Quimbo R, Vangerow B, Toth PP

Get full text

Effect of evolocumab on lipoprotein particles by Toth, PP, Sattar, N, Blom, DJ, Martin, SS, Jones, SR, Monsalvo, ML, Elliott, M, Davis, M, Somaratne, R, Preiss, D